These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 16005749)

  • 1. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
    Robert Putnak J; Coller BA; Voss G; Vaughn DW; Clements D; Peters I; Bignami G; Houng HS; Chen RC; Barvir DA; Seriwatana J; Cayphas S; Garçon N; Gheysen D; Kanesa-Thasan N; McDonell M; Humphreys T; Eckels KH; Prieels JP; Innis BL
    Vaccine; 2005 Aug; 23(35):4442-52. PubMed ID: 16005749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
    Putnak R; Fuller J; VanderZanden L; Innis BL; Vaughn DW
    Am J Trop Med Hyg; 2003 Apr; 68(4):469-76. PubMed ID: 12875299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
    Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
    Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
    Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
    Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
    Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N
    Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
    Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
    Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris.
    Guzmán MG; Rodríguez R; Rodríguez R; Hermida L; Alvarez M; Lazo L; Muné M; Rosario D; Valdés K; Vázquez S; Martinez R; Serrano T; Paez J; Espinosa R; Pumariega T; Guillén G
    Am J Trop Med Hyg; 2003 Aug; 69(2):129-34. PubMed ID: 13677367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.
    Raviprakash K; Apt D; Brinkman A; Skinner C; Yang S; Dawes G; Ewing D; Wu SJ; Bass S; Punnonen J; Porter K
    Virology; 2006 Sep; 353(1):166-73. PubMed ID: 16814355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys.
    Blair PJ; Kochel TJ; Raviprakash K; Guevara C; Salazar M; Wu SJ; Olson JG; Porter KR
    Vaccine; 2006 Feb; 24(9):1427-32. PubMed ID: 16214271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
    Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
    Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
    J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
    Hanley KA; Manlucu LR; Manipon GG; Hanson CT; Whitehead SS; Murphy BR; Blaney JE
    Vaccine; 2004 Sep; 22(25-26):3440-8. PubMed ID: 15308370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
    Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.
    Simmons M; Porter KR; Hayes CG; Vaughn DW; Putnak R
    J Virol; 2006 Oct; 80(19):9577-85. PubMed ID: 16973561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.
    Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG
    Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.